Tislelizumab plus chemoradiation before surgery for stomach cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This Phase 2 trial studies giving tislelizumab (an immune therapy) together with pre-surgery chemoradiation for locally advanced stomach or GEJ (esophagus-stomach junction) adenocarcinoma. It compares this approach to the standard treatment (chemoradiation plus surgery) to see if it improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have not had treatment yet for localized stomach or GEJ adenocarcinoma that has grown locally (not distant metastasis).
- Your general strength/fitness is fairly good (ECOG 0 to 1).
- Your blood, kidney, and liver tests are good enough for treatment.
- If you can have a pregnancy: you must use reliable birth control during the study and for a period after the last chemotherapy dose (and possibly longer after certain drug dosing).
- You must not have had prior cancer medicines or investigational anti-cancer drugs for this current cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of immunotherapy and chemotherapy given before surgery to shrink stomach cancers that are particularly thick or large. It aims to see if this approach can make these hard-to-treat tumors easier to remove and improve outcomes.
This trial tests a combination of immune therapy and chemotherapy given before surgery for stomach or esophagus-stomach cancer. The goal is to shrink the tumor to make surgery more effective and possibly improve outcomes.
This trial compares two types of chemotherapy with or without an immunotherapy drug (tislelizumab) for advanced stomach or gastroesophageal junction cancer. It aims to see which combination works better and has fewer side effects.
This trial tests a combination of an immunotherapy drug (sintilimab) and two chemotherapy drugs (nab-paclitaxel and tegafur) as a first treatment for stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread. The goal is to see if this combination helps people live longer and controls the cancer better.
This trial tests a combination of chemotherapy, low-dose radiation, and an immunotherapy drug called tislelizumab for patients with stomach or gastroesophageal junction cancer that has not spread to distant organs. The goal is to see if this combination can shrink tumors and improve outcomes before and after surgery.
This trial tests adding an immunotherapy drug (tislelizumab) to standard chemotherapy (FLOT) before surgery for people with stomach or esophagus cancer that can be removed but hasn't spread. The goal is to see if this combination is safe and works better than chemotherapy alone.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.